Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer

Naiyer A, Rizvi,MD
Published Online: Sunday, Nov 10, 2013


Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Rizvi says the anti-PD-1 antibodies nivolumab and MK-3475, and the anti-PD-L1 antibody MPDL3280A, are all being developed as treatments for stage IV lung cancer. Early studies of these agents have shown a response rate in the 20% range in patients with heavily pre-treated lung cancer who are resistant to chemotherapy and have failed all standard therapies. Rizvi says a 20% response rate is very encouraging for this group of patients.

Many of these patients have also showed durable responses, Rizvi says. Recently, the data from the nivolumab trial were updated to show a 2-year survival of 24%, which Rizvi says is a very high number for that patient population.

<<< View coverage from the New York Lung Cancer Symposium


Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Rizvi says the anti-PD-1 antibodies nivolumab and MK-3475, and the anti-PD-L1 antibody MPDL3280A, are all being developed as treatments for stage IV lung cancer. Early studies of these agents have shown a response rate in the 20% range in patients with heavily pre-treated lung cancer who are resistant to chemotherapy and have failed all standard therapies. Rizvi says a 20% response rate is very encouraging for this group of patients.

Many of these patients have also showed durable responses, Rizvi says. Recently, the data from the nivolumab trial were updated to show a 2-year survival of 24%, which Rizvi says is a very high number for that patient population.

<<< View coverage from the New York Lung Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Newer Options on the Horizon for Non-Small Cell Lung CancerJul 20, 20161.0
Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations - Online ActivityJul 31, 20161.5